Shanghai Pharmaceuticals Holding Co. (SH Pharma) reported third-quarter 2026 revenue of RMB 75.49 billion, a 2.74% year-on-year increase, lifting nine-month sales to RMB 222.96 billion (+3.67%). Pharmaceutical services remained the main growth engine, contributing RMB 203.98 billion (+3.59%) for the January–September period, while pharmaceutical manufacturing sales reached RMB 18.99 billion (+4.54%).
Third-quarter profitability rebounded sharply on lower impairment charges: total profit rose 30.29% to RMB 1.92 billion, and net profit attributable to shareholders advanced 57.15% to RMB 1.08 billion. Core net profit (after excluding non-recurring items) expanded 49.69% to RMB 896.79 million. Basic earnings per share for the quarter climbed 52.63% to RMB 0.29.
For the first nine months, reported net profit attributable to shareholders fell 10.90% to RMB 4.59 billion, reflecting a high base of one-off gains in 2025. Adjusted net profit, however, improved 25.02% to RMB 3.37 billion, underscoring stronger operating fundamentals. Operating cash inflow more than doubled to RMB 5.35 billion (+127.54%), supporting total assets of RMB 242.05 billion (+3.82% versus end-2025) and shareholder equity of RMB 79.34 billion (+4.55%).
R&D expenditure totaled RMB 1.52 billion during the nine-month period, equivalent to 7.98% of manufacturing sales. The company’s pipeline reached 60 clinical or CTA-cleared programs. Highlights include BCD-085 (anti-IL-17 mAb) progressing through China FDA technical review for ankylosing spondylitis and a filing for plaque psoriasis; Shenqi Sherong Pill (TCM Class 1.1) entered pre-NDA discussions; and Phase III studies for SRD4610 (Huoling Shengji Granules) and SHPL-49 injection surpassed mid-enrolment.
In generic and international markets, SH Pharma secured 13 production approvals and eight consistency-evaluation clearances. Subsidiary Sine Ruijue executed first commercial shipments of Mometasone Furoate Nasal Spray to the US, marking the group’s entry into complex drug-device exports. Consumer health subsidiaries accelerated launches in infant nutrition, anti-aging and ophthalmology segments.
The pharmaceutical services arm reinforced its nationwide supply-chain platform, expanded CSO and SPD businesses, and deepened alliances with companies including Rongchang Pharmaceutical, Johnson & Johnson MedTech and Alfasigma. Progress on a “New Retail Integration Strategy” saw the consolidation of 24 out of 34 targeted specialty pharmacy entities, aimed at scaling SPH Cloud Health’s retail network.
As of 30 September 2026, SH Pharma’s capital structure remained stable, with short-term borrowings of RMB 44.74 billion and a cash balance of RMB 32.40 billion. The weighted average return on equity for the nine months stood at 5.90%, down 1.06 percentage points year on year, reflecting the lower headline profit but underpinned by resilient operating performance and strengthened cash generation.